Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr Ildiko Lingvay is a Tenured Professor of Medicine in the Division of Endocrinology and Professor in the Peter O’Donnell Jr School of Public Health at UT Southwestern Medical Center, Dallas, TX, USA. Dr Lingvay is also the Medical Director of the Office of Clinical Trials Management, overseeing all clinical trials at UT Southwestern. She is Board Certified in Obesity Medicine, as well as in Endocrinology, Diabetes and Metabolism.
Dr Lingvay leads a programme that focuses on clinical research in the field of obesity and type 2 diabetes, with the ultimate goal of improving the lives of all patients who suffer health consequences as a result of their medical problems. Her research interests span the spectrum from pathophysiology of the disease to treatment algorithms and comparative effectiveness of various therapeutic approaches. Dr Lingvay treats patients at the UT Southwestern clinics and hospitals, as well as at the Parkland Health & Hospital System.
Dr Lingvay is an active member of the American Diabetes Association, where she has served over the years on several committees, including the Organizing Committee for the Annual Scientific Sessions, Focus on Fellows Advisory Board, WIN-ADA Advisory Board, Grant Review Committee and the Professional Practice Committee. She is on the Editorial Board of several journals, including Diabetes Care. She has participated in approximately 100 clinical trials and has a special interest in cardiovascular outcome trials and obesity trials. She has authored more than 140 publications in major medical journals and has authored chapters in several popular diabetes textbooks.
Subodh Verma
University of Toronto, Toronto, Canada
Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr Verma is a Fellow of the Canadian Academy of Health Sciences, one of the highest national honours that recognizes scholars for their promotion of health science. In 2022, Dr Verma was named a Clarivate Highly Cited Researcher in Clinical Medicine. In 2021, he was bestowed the University of Toronto Lister Prize in Surgery in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research from the International Academy of Cardiovascular Sciences and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. Dr Verma is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the Royal Society of Canada College of New Scholars, Artists and Scientists.
Dr Verma’s over 500 peer-reviewed publications have earned him a Google Scholar h-index of 115 with nearly 60,000 citations. He has published extensively in highly impactful journals like the NEJM, Lancet, Nature, Circulation, European Heart Journal and JACC. He is an Associate Editor of the European Heart Journal and a Section Editor of Current Opinion in Cardiology. Dr Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was also a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr Verma is the current Scientific Program Committee Chair for the Canadian Society of Cardiac Surgeons and has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.
Dr Verma had/has leadership roles in multiple contemporary global heart failure trials – several of which persuaded guideline writing committees to recommend paradigm changes in how individuals who live with heart failure should be managed. He founded the CardioLink platform at St Michael’s Hospital that united cardiac surgeons from across Canada to conduct robust clinical trials to better inform on surgical decisionmaking pathways. CardioLink has since expanded its scope to include cardiometabolic studies.
Dr Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiometabolic diseases. His current research is centred around modulating vascular regenerative cell exhaustion to alleviate cardiometabolic risk. Dr Verma holds 2 United States patents, and his research program is supported by national peer-reviewed grants.
Read full bio
Nikolaus Marx
University Hospital Aachen, Aachen, Germany
Nikolaus Marx, born in 1968, is Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany. He received his medical training at the Universities of Mainz, Genf (Switzerland) and Düsseldorf, obtaining his MD in 1994. His thesis on growth regulation in human renal cancer cell lines was completed at the laboratory of Professor Gerharz at the Institute of Pathology, University of Mainz. After a post-doctoral fellowship with Dr. Peter Libby and Dr. Jorge Plutzky at Brigham and Women's Hospital, Harvard Medical School, Nikolaus Marx later became a board-certified internist, then cardiologist, before specialising in intensive care medicine in internal medicine at the University of Ulm. He was appointed Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I at the University of Aachen in 2009.
Professor Marx is a member of several organisations within the field of cardiology and diabetes, including the European Society of Cardiology, American Heart Association (AHA), German Diabetes Association and the European Association for the Study of Diabetes. In addition to reviewing submitted manuscript to numerous journals, including Circulation, Diabetologia, Diabetes, Diabetes Care, the Journal of Immunology and The Lancet, he is currently Associate Editor for European Heart Journal. Professor Marx was awarded the Servier Young Investigators Award in 1999 at the First European Meeting on Vascular Biology and Medicine, the 2004 Morgagni Young Investigator Award as well as the Rising Star Award 2005 of the European Association for the Study of Diabetes (EASD). Professor Marx has served as President of the German Atherosclerosis Society (DGAF) from 2012 to 2015. He has been a board member of the German Society of Cardiology (DGK) from 05/2017 to 04/2019 .
Read full bio